Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

UCH-L1 (human), (recombinant) (His-tag)

 
BML-UW9740-0050 50 µg 256.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Ubiquitin C-terminal hydrolase L1, PGP9.5
 
MW:24.8 kDa
 
Source:Produced in E. coli.
 
UniProt ID:P09936
 
Formulation:Liquid. In 50 mM TRIS, pH 7.6, containing 1 mM dithiothreitol (DTT).
 
Specific Activity:>100 pmol/min/µg. Determined at 25°C with 1 μM ubiquitin-AMC (BML-SE211) as substrate and UCH-L1 (see protocol).
 
Shipping:Shipped on Dry Ice
 
Long Term Storage:-80°C
 
Scientific Background:Ubiquitin C-terminal hydrolases (UCHs) are a family of cysteine hydrolases that catalyze the hydrolysis of amides, esters and thioesters of the C-terminus of ubiquitin. Mammalian neuronal cells abundantly express a deubiquitylating enzyme, ubiquitin carboxy-terminal hydrolase 1 (UCH-L1). Mutations in UCH-L1 are linked to Parkinson's disease as well as gracile axonal dystrophy (gad) in mice. In contrast to the universally expressed UCH-L3 isozyme, UCH-L1 is expressed exclusively in neurons and testis/ovary. It has been shown that UCH-L1 associates and co-localizes with monoubiquitin and elongates ubiquitin half-life and the suggestion is made that UCH-L1, with avidity and affinity for ubiquitin, ensures ubiquitin stability within neurons.
 
Protocol:Components of Assay:
Assay Buffer: 50 mM HEPES/NaOH, pH 7.8, 0.5 mM EDTA, 1 mM DTT, 0.1 mg/ml ovalbumin
UCH-L1 (BML-UW9740): Dilute to 20-fold the desired final concentration in cold Assay Buffer (e.g. 400 pM/10.8 ng/ml), and keep on ice until use.
Ubiquitin-AMC (BML-SE211): 0.542 mg/ml (62 µM) solution in 50 mM sodium acetate, pH 7.0. Prepare a dilution in Assay Buffer which is 20-fold the desired assay concentration.
AMC Standard (BML-KI107): 30 µM solution in 50 mM HEPES/NaOH, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1 mM EDTA, 10% glycerol. Prepare a series of dilutions in Assay Buffer (0-1.0 µM) for use in preparation of a standard curve.
½ Volume 96-well white micro-plate (BML-KI110)
Microplate-reading Fluorimeter: Reader should be capable of excitation at a wavelength in the range of 350-380 and detection of emitted light in the range of 440-460 nm.

Assay Procedure:
  1. Add 90 µl of Assay Buffer to the desired number of microplate wells and warm to assay temperature (e.g. 25°C).
  2. Add 5 µl of diluted UCH-L1 and incubate for 30 min. to allow time for DTT-mediated activation of the enzyme.
  3. Start the reaction by adding 5 µl of the 20x ubiquitin-AMC and mixing well. The Km of this preparation of UCH-L1 for ubiquitin-AMC was determined to be 57 nM and assays are typically performed at final concentrations in the range of 0-1 µM.
  4. Monitor the progress of the reaction by measuring the fluorescence of the AMC cleaved from the ubiquitin-AMC. For example, read fluorescence (Ex. 350-380 nm; Em. 440-460) at 1 min. intervals for 10 min.
  5. Determine the fluorescence in wells filled with 100 µl of a series of dilutions of AMC in Assay Buffer (0-1 µM). Plot AMC concentration (µM, y-axis) as a function of fluorescence (arbitrary fluorescence units, AFU, x-axis).
  6. Data analysis: A conversion factor relating fluorescence to AMC concentration may be determined from the slope of the line (µM/AFU) obtained in step 5). Initial rates of ubiquitin-AMC cleavage by UCH-L1 may be determined from the slope (AFU/min) of the early, linear part of the reaction progress curve. A rate in, for example, pmol/min, can then be calculated by multiplying the initial slope of the progress curve by the slope of the calibration curve and the reaction volume (100 µl): Rate (pmol/min) = (AFU/min) x (µM/AFU) x (100 µl)
 

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Catalogs
Ubiquitin & UBL Signaling Catalog
Ubiquitin & UBL Signaling Catalog
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,